- Home
- CSR vs CGEM Comparison
CSR vs CGEM Comparison
Compare CSR & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSR | CGEM |
|---|---|---|
| Founded | 1970 | 2016 |
| Country | United States | United States |
| Employees | 349 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.8M | 873.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CSR | CGEM |
|---|---|---|
| Price | $61.04 | $14.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $69.80 | $30.11 |
| AVG Volume (30 Days) | 100.8K | ★ 715.7K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.24 | N/A |
| Revenue Next Year | $2.72 | $5.20 |
| P/E Ratio | $62.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.76 | $5.68 |
| 52 Week High | $69.15 | $16.74 |
Technical Indicators
Market Signals| Indicator | CSR | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 55.35 | 58.89 |
| Support Level | $60.01 | $11.75 |
| Resistance Level | $68.36 | $16.74 |
| Average True Range (ATR) | 1.50 | 0.96 |
| MACD | 0.40 | 0.13 |
| Stochastic Oscillator | 87.50 | 77.45 |
Price Performance
Historical ComparisonAbout CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.